SIMTRIYO (Centanafadine) FDA Approval for ADHD Otsuka Receives FDA Approval for SIMTRIYO® (Centanafadine) First-in-Class Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) July 24, 2026 Introduction to ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder characterized primarily by persistent patterns of inattention, hyperactivity, and impulsivity. These symptoms can significantly interfere with academic performance, occupational functioning, social relationships, and overall daily life. Although ADHD is most often diagnosed in childhood, symptoms frequently continue into adolescence and adulthood. In the United States, ADHD affects approximately 7 million children and an estimated 15.5 million adults , totaling around 22.5 million people . Because ADHD is highly individualized, treatment needs vary widely among patients, and hav...
Posts
Showing posts from August 9, 2026